While a reduction in cholesterol efflux is a well-established aspect of the innate immune system during acute infections, it may have long-term negative implications under conditions of chronic inflammatory stress [
15]. Numerous studies have shown that this vital homeostatic process may become impaired by a number of structural and conformational changes within HDL particles exposed to acute or chronic inflammatory conditions. The incorporation of SAA has been shown to impair cholesterol efflux in some [
50‐
53], but not all [
42,
54], studies. These changes may arise through the displacement of atheroprotective components such as ApoA-I or PON-1 within the HDL particle itself [
50], or by interactions with cell membrane-bound receptors responsible for binding HDL during the RCT process. In mice overexpressing SAA, reduced binding of HDL to SR-BI and a reduction in selective hepatic cholesterol ester uptake from HDL has been observed in conjunction with elevated levels of lipid-free SAA, suggesting a reduced capacity for the liver to remove cholesterol esters for excretion [
53]. Further upstream in the RCT pathway, genetic ablation of SAA has been observed to preserve cholesterol efflux in mice following an endotoxin challenge, whereas the same challenge in humans resulted in progressive decreases in efflux capacity in line with elevations in the content of HDL-incorporated SAA [
51]. Furthermore, an increased affinity for HDL to bind to proteoglycans at peripheral sites has also been demonstrated following SAA elevation in endotoxin-injected mice [
55]. This effect is again virtually abolished following SAA knockout, suggesting that the incorporation of SAA into HDL may further impair RCT through the entrapment of HDL within vascular lesions, where its contents may subsequently be liable to oxidation or enzymatic modification that render it more atherogenic [
55]. In support of this, a number of studies have demonstrated extensive structural and functional changes within HDL particles located within the vessel wall in comparison to those circulating in the bloodstream [
56‐
58], resulting in a substantially dysfunctional HDL phenotype which is unable to promote cholesterol efflux. For example, ApoA-I isolated from human atherosclerotic plaques has been shown to be lipid-poor, heavily oxidised by the inflammatory enzyme myeloperoxidase (MPO), and virtually devoid of any cholesterol acceptor activity [
59]. This dysfunctional form of ApoA-I—which may also be caused by chlorination, nitration, or sulfoxidation of other amino acid residues—appears to exert its detrimental effects via multiple sites of action, including impairment of ABCA1 cholesterol efflux [
58,
60,
61] and decreased ApoA-I-induced activation of LCAT [
62]. Further inhibition of ABCA1 via an accumulation of the lipid peroxidation product MDA (a reactive carbonyl that has been shown to increase in HDL in chronic disease states) has also been demonstrated [
63], while HDL-enrichment with triglycerides has been shown to impact RCT in some, but not all, studies. These latter findings may perhaps seem counter-intuitive given the finding that triglyceride-enriched HDL may in fact increase macrophage cholesterol efflux [
64‐
66]. However, they are likely explained by further downstream effects that may affect overall RCT, including a reduced ability for LCAT to convert free cholesterol to cholesterol esters [
64], and a diminished capacity to deliver these cholesterol esters to hepatic cells via SR-BI [
64,
67]. HDL remodelling due to elevated PLTP activity may also adversely affect cholesterol acceptor ability, and has been shown to result in increased atherosclerotic plaque formation in mice [
68].